Elevated FUS/TLS expression is negatively associated with E‑cadherin expression and prognosis of patients with non‑small cell lung cancer

Xiong,Dian; Wu,Yong‑Bing; Jin,Chun; Li,Ji‑Jun; Gu,Jie; Liao,Yun‑Fei; Long,Xiang; Zhu,Shu‑Qiang; Wu,Hai‑Bo; Xu,Jian‑Jun; Ding,Jian‑Yong

doi:10.3892/ol.2018.8816

Elevated FUS/TLS expression is negatively associated with E‑cadherin expression and prognosis of patients with non‑small cell lung cancer

Authors:
- Dian Xiong
- Yong‑Bing Wu
- Chun Jin
- Ji‑Jun Li
- Jie Gu
- Yun‑Fei Liao
- Xiang Long
- Shu‑Qiang Zhu
- Hai‑Bo Wu
- Jian‑Jun Xu
- Jian‑Yong Ding
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Thoracic Surgery, The Affiliated Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
Published online on: May 25, 2018 https://doi.org/10.3892/ol.2018.8816
Pages: 1791-1800

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fused in sarcoma/translocated in liposarcoma (FUS/TLS), a ubiquitous and multifunctional DNA and RNA‑binding protein, contributes an important function in cancer and neurodegenerative disease; however, its role in lung cancer remains unclear. In the present study, the expression of FUS/TLS in non‑small cell lung cancer (NSCLC) and the significance of FUS/TLS for predicting the clinical outcome of patients with NSCLC, was examined. FUS/TLS expression was investigated in NSCLC tissues and their matched adjacent non‑tumorous tissues by reverse transcription‑quantitative polymerase chain reaction, western blotting, and immunohistochemistry. Tissue microarrays representing 208 patients with NSCLC were used to determine the expression pattern and associations with FUS/TLS using immunohistochemistry. Prognostic significance was assessed by Kaplan‑Meier survival estimates and log‑rank tests. Data revealed that FUS/TLS expression was elevated in NSCLC tissues compared with corresponding normal tissue mRNA (9.27±0.73 vs. 6.15±0.60) and protein (3.32±0.75 vs. 0.30±0.07) levels. In tissue microarrays, FUS/TLS was highly expressed in 103 (49.5%, 103/208) NSCLC tissues compared with adjacent normal lung tissues (28.4%, 59/208). Overexpression of FUS/TLS was associated with higher tumor node metastasis stage (P=0.016), poorer differentiation (P=0.008), large tumor size (P=0.019) and predicted poor prognosis (P=0.005) in patients with NSCLC. Notably, correlation analysis revealed a significant inverse association between the expression of FUS/TLS and E‑cadherin (r2=0.51; P=0.036). Furthermore, patients with NSCLC with high FUS/TLS and impaired E‑cadherin expression had a notably poor prognosis (P=4.01x10‑4). Thus, the results from the present study indicate that elevated FUS/TLS expression promotes NSCLC progression. FUS/TLS, alone or in combination with E‑cadherin, is a novel prognostic predictor for patients with NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, et al: NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 14:255–264. 2016. View Article : Google Scholar : PubMed/NCBI
3	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
4	Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C, et al: FUS-DDIT3 fusion protein driven IGF-IR signaling is a therapeutic target in myxoid liposarcoma. Clin Cancer Res. 23:6227–6238. 2017. View Article : Google Scholar : PubMed/NCBI
5	Morohoshi F, Ootsuka Y, Arai K, Ichikawa H, Mitani S, Munakata N and Ohki M: Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes. Gene. 221:191–198. 1998. View Article : Google Scholar : PubMed/NCBI
6	Bertolotti A, Bell B and Tora L: The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties. Oncogene. 18:8000–8010. 1999. View Article : Google Scholar : PubMed/NCBI
7	Zinszner H, Albalat R and Ron D: A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 8:2513–2526. 1994. View Article : Google Scholar : PubMed/NCBI
8	Lerga A, Hallier M, Delva L, Orvain C, Gallais I, Marie J and Moreau-Gachelin F: Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem. 276:6807–6816. 2001. View Article : Google Scholar : PubMed/NCBI
9	Nguyen CD, Mansfield RE, Leung W, Vaz PM, Loughlin FE, Grant RP and Mackay JP: Characterization of a family of RanBP2-type zinc fingers that can recognize single-stranded RNA. J Mol Biol. 407:273–283. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN and Reddy ES: The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene. 9:3087–3097. 1994.PubMed/NCBI
11	Cassiday LA and Maher LJ III: Having it both ways: Transcription factors that bind DNA and RNA. Nucleic Acids Res. 30:4118–4126. 2002. View Article : Google Scholar : PubMed/NCBI
12	Panagopoulos I, Aman P, Mertens F, Mandahl N, Rydholm A, Bauer HF and Mitelman F: Genomic PCR detects tumor cells in peripheral blood from patients with myxoid liposarcoma. Genes Chromosomes Cancer. 17:1021996. View Article : Google Scholar : PubMed/NCBI
13	Campos-Melo D, Droppelmann CA, Volkening K and Strong MJ: RNA-binding proteins as molecular links between cancer and neurodegeneration. Biogerontology. 15:587–610. 2014. View Article : Google Scholar : PubMed/NCBI
14	Riggi N, Cironi L, Suva ML and Stamenkovic I: Sarcomas: Genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol. 213:4–20. 2007.
15	Crozat A, Aman P, Mandahl N and Ron D: Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 363:640–644. 1993. View Article : Google Scholar : PubMed/NCBI
16	Ichikawa H, Shimizu K, Hayashi Y and Ohki M: An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54:2865–2868. 1994.PubMed/NCBI
17	Kong XT, Ida K, Ichikawa H, Shimizu K, Ohki M, Maseki N, Kaneko Y, Sako M, Kobayashi Y, Tojou A, et al: Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood. 90:1192–1199. 1997.PubMed/NCBI
18	Spitzer JI, Ugras S, Runge S, Decarolis P, Antonescu C, Tuschl T and Singer S: mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes Cancer. 50:338–347. 2011. View Article : Google Scholar : PubMed/NCBI
19	Ke H, Zhao L, Feng X, Xu H, Zou L, Yang Q, Su X, Peng L and Jiao B: NEAT1 is required for survival of breast cancer cells through FUS and miR-548. Gene Regul Syst Bio. 10:11–17. 2016.PubMed/NCBI
20	Lepourcelet M, Tou L, Cai L, Sawada J, Lazar AJ, Glickman JN, Williamson JA, Everett AD, Redston M, Fox EA, et al: Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 132:415–427. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
22	Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA and Franklin WA: High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 20:2417–2428. 2002. View Article : Google Scholar : PubMed/NCBI
23	Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, Stenman G, Nilsson O and Aman P: The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 9:372008. View Article : Google Scholar : PubMed/NCBI
24	Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 153:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
25	Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, Guo J and Ge D: Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 81:259–265. 2013. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ and Ding JY: High level of BRD4 promotes non-small cell lung cancer progression. Oncotarget. 7:9491–9500. 2016. View Article : Google Scholar : PubMed/NCBI
28	Liao Y, Gu J, Wu Y, Long X, Ge DI, Xu J and Ding J: Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer. Oncol Lett. 11:3753–3760. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhao GY, Ding JY, Lu CL, Lin ZW and Guo J: The overexpression of 14-3-3ζ and Hsp27 promotes non-small cell lung cancer progression. Cancer. 120:652–663. 2014. View Article : Google Scholar : PubMed/NCBI
30	Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M and Okamoto T: Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem. 276:13395–13401. 2001. View Article : Google Scholar : PubMed/NCBI
31	Zinszner H, Sok J, Immanuel D, Yin Y and Ron D: TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci. 110:1741–1750. 1997.PubMed/NCBI
32	Mastrocola AS, Kim SH, Trinh AT, Rodenkirch LA and Tibbetts RS: The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J Biol Chem. 288:24731–24741. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ward CL, Boggio KJ, Johnson BN, Boyd JB, Douthwright S, Shaffer SA, Landers JE, Glicksman MA and Bosco DA: A loss of FUS/TLS function leads to impaired cellular proliferation. Cell Death Dis. 5:e15722014. View Article : Google Scholar : PubMed/NCBI
34	Panagopoulos I, Aman P, Fioretos T, Höglund M, Johansson B, Mandahl N, Heim S, Behrendtz M and Mitelman F: Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer. 11:256–262. 1994. View Article : Google Scholar : PubMed/NCBI
35	Haile S, Lal A, Myung JK and Sadar MD: FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS One. 6:e241972011. View Article : Google Scholar : PubMed/NCBI